Daniel Hollander, The Eli and Edythe Broad Foundation

TITLE: Director of Scientific and Medical Research Initiatives

FUNDING AREAS: Digestive diseases and disorders

CONTACT: Visit PeopleFinder for email and phone number (paid subscribers only)

IP TAKE: Given his extensive background and expertise, Hollander is a great fit to lead Broad's charge against digestive diseases such as Crohn's disease and ulcerative colitis. 

PROFILE: With over $2 billion in assets, The Eli and Edythe Broad Foundation has much to contribute to its stated focus areas of education, science, and the arts. Daniel Hollander, M.D., who is also a professor of medicine at UCLA, heads up a subset of the foundation's scientific work: Medical research focusing on finding cures for inflammatory bowel disease (IBD).

Approximately 1.4 million Americans suffer from Crohn's disease or ulcerative colitis, two types of IBD that are similar in many ways but differ in their location and severity of inflammation. Although IBD has no known cause or cure, it manifests itself in often debilitating ways. IBD sufferers have inflamed gastrointestinal tracts and experience uncomfortable symptoms such as frequent diarrhea and rectal bleeding. Eventually, people living with IBD can experience more life-threatening complications, such as anemia, malnutrition, and colon cancer.

The effects of IBD are something Eli and Edyth Broad, the founders of this granting source, know well. Alarmed by a family member's experience with IBD, the exceedingly wealthy and philanthropically-minded pair decided to devote a portion of their foundation's resources to investigating what exactly causes this common disease and how IBD can be more effectively treated.

In 2001 The Eli and Edythe Broad Foundation announced the creation of the Broad Medical Research Program for Inflammatory Bowel Disease, to be headed up by Hollander, a respected IBD specialist and medical research director. Before The Broad Foundation, Hollander was president and CEO of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Previous to that, he was executive dean and professor of medicine at the University of Kansas School of Medicine and head of the Division of Gastroenterology at the University of California, Irvine, where he was also  associate dean for research and program development, associate dean for academic affairs, and senior associate dean for clinical affairs. So besides knowing the medical industry in which he grants, Hollander also knows how to run things.

In a press release about the newly created IBD initiative, Hollander is quoted as saying, "I would like nothing better than to be inundated with outstanding, novel research proposals." And inundated he has been. Over the years, Broad has funded hundreds of IBD-related research initiatives around the globe, with grants totalling more than $37.3 million.

Recent data show that Broad spends about $3.5 million annually on IBD research, with a mean annual per grant funding of $114,082. The recipients of Broad funding tackle the IBD problem from different perspectives, specializing in research areas as far ranging as genetics, immunology, and "enteric flora interaction with the gut."

Broad accepts research proposals on an ongoing basis from any non-profit institution with an innovative project aimed at improving the health and well-being of people suffering with IBD. Additionally, Broad is currently accepting more specific proposals on how IBD incidences differ in developed versus developing countries. This focus probably stems from the curious discovery that IBD is more commonly diagnosed in Western, industrialized countries than in other regions of the world.

Should Hollander and his team be successful in finally pinpointing a cause or a cure for IBD, the potential impact of Broad's work for millions of people around the world is just huge. So it is not surprising that The Chronicle of Philanthropy reports that Hollander is among the "top charity executives" in America. (The publication also reports Hollander's annual salary, which is itself impressive, even if it equates to a relatively small percentage of Broad's overall IBD budget.)

Groups interested in soliciting Broad for IBD funding can find relevant information here